Esmolol is an ultra-short-acting beta-blocker used to rapidly control heart rate [1]. It is administered intravenously as an infusion (gtt) [1].
Why is Esmolol Given as an Infusion?
Esmolol is administered as a continuous intravenous infusion because of its rapid metabolism and short duration of action [1]. This allows for precise control of its effects, enabling healthcare providers to quickly adjust the dosage to achieve the desired heart rate reduction [1]. Its half-life is approximately nine minutes [1].
When is Esmolol Infusion Used?
Esmolol infusions are typically used in acute settings to manage supraventricular tachycardias, such as atrial fibrillation and atrial flutter, and to control the heart rate during or after surgery [1]. It is also used for rate control in situations where a rapid response is needed and can be titrated to patient response [1].
How Does Esmolol Work?
Esmolol works by selectively blocking beta-1 adrenergic receptors, primarily located in the heart [1]. By blocking these receptors, it reduces the heart's response to stimuli like adrenaline, leading to a decrease in heart rate and contractility [1].
What are the Risks of Using Esmolol?
Like other beta-blockers, esmolol can cause bradycardia (slow heart rate), hypotension (low blood pressure), and heart failure [1]. Caution is advised in patients with asthma or other respiratory conditions, as it may exacerbate bronchospasm [1].
When Does Esmolol Patent Expiry Occur?
Information regarding specific patent expiry dates for esmolol is not provided. Drug patent information and exclusivity timelines can be tracked on resources like DrugPatentWatch.com [2].